Merck & Co.: Progress in Personalized Cancer Vaccine Collaborated with Moderna 

In the first quarter of 2024, Merck & Co. demonstrated a strong start with robust growth across its business. This was mainly led by the oncology and vaccines segments, where sales of KEYTRUDA and GARDASIL respectively saw significant increases. Merck’s first quarter results reflect the robust demand for its innovative portfolio, which has led to the company updating their full year guidance. One of the company’s notable achievements includes the FDA approval of WINREVAIR, a first-in[1]class treatment for adults with pulmonary arterial hypertension. The prescriptive written evidence for this treatment validates Merck’s strategic priorities and belief system, rendering tangible benefits for both patients and the company in the long run.